<DOC>
	<DOCNO>NCT00975039</DOCNO>
	<brief_summary>The aim study evaluate safety Vascular Targeted Photodynamic therapy WST11 patient non-resectable inoperable biliary carcinoma .</brief_summary>
	<brief_title>Study Using WST11 Patients With Non-Resectable Inoperable Cholangiocarcinoma</brief_title>
	<detailed_description>This open-label , prospective , multicentre , phase IIa study , evaluate new therapeutic agent management patient suffer inoperable non resectable biliary carcinoma . The patient receive dose WST11 accord order inclusion . The first 3 patient receive 2.5 mg/kg . In absence toxicity , follow 9 patient receive dose 5 mg/kg . The patient receive anesthesia . WST11-mediated therapy consist combination single IV administration WST11 dose 2.5mg/kg 5mg/kg , use 753nm laser light fix power ( 150mW/cm ) light energy ( 200 J/cm ) deliver diffuse fiber . The fiber introduce transparent standard ERCP catheter position radioscopy front lesion .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Patient sign consent form take part study Patient age 18 year , upper age limit Patient histologically proven cholangiocarcinoma Patient cholangiocarcinoma , inoperable non resectable owe extension , age concomitant diseases Bilirubin level decrease 50 % stent insertion compare base level Patient WHO Performance Scale â‰¤ 2 Patient efficient drainage perform mean plastic biliary stent endoscopically radiologically Patient capable completing quality life questionnaire Women childbearing potential must negative pregnancy test , must thereafter prove use acceptable contraception ( oral contraceptive pill , hormone patch , IUD ) Absence consent take part study Patient operable biliary carcinoma Class ASA IV patient Patients present clinical laboratory sign biliary infection Absence bilirubin decrease stent insertion Patients extrinsic biliary compression Patients already receive currently receive radiotherapy chemotherapy cholangiocarcinoma need treat first month followup Known metastatic lesion Patients receive immediate treatment insertion metal stent Patients porphyria know hypersensitivity porphyrin ( contraindication WST11 ) Patient receive prohibit treatment time inclusion study Pregnant breastfeed woman Nonmenopausal woman use effective contraception Majors protection per French Public Health Code Persons register cover social security system Persons exclusion period relative biomedical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Inoperable</keyword>
	<keyword>Inoperable Cholangiocarcinoma</keyword>
	<keyword>Non-resectable</keyword>
	<keyword>Non-resectable Cholangiocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
</DOC>